Effect of Continuous Erector Spinae Plane Block With Ropivacaine on Postoperative Pain and NF-κB Levels After Mastectomy

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age30-65
SponsorAldy Aldy

About this trial

This study aims to evaluate the effect of continuous erector spinae plane block (CESPB) using ropivacaine on postoperative pain in patients undergoing elective mastectomy. In addition to pain control, this study investigates the impact of CESPB on systemic inflammatory response as measured by nuclear factor kappa B (NF-κB) levels, opioid consumption, and quality of recovery. Patients will be randomly assigned to receive CESPB or standard analgesia without block. Outcomes will be assessed within the first 24 hours after surgery. The findings are expected to provide evidence on the clinical and biological benefits of CESPB as part of multimodal analgesia in breast surgery.

Eligibility criteria

Qualifiers

Female patients aged 18 to 65 years

Diagnosed with breast cancer

Scheduled for elective mastectomy under general anesthesia

American Society of Anesthesiologists (ASA) physical status I-III

Disqualifiers

Contraindications to regional anesthesia

Contraindications or allergy to ropivacaine or local anesthetics

Inability to use a visual analog scale (VAS) for pain assessment

Inability to understand or operate patient-controlled analgesia (PCA)

Trial design

Treatments tested in this trial

  • Continuous Erector Spinae Plane Block
  • Ropivacaine

Treatment groups

40 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Aldy Aldy

Lead sponsor

Udayana University

Sponsor institution